Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($1.10), $0.42 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $1.4 million.

CEO COMMENTS:

President and CEO Katrine Bosley commented “2017 is already shaping up to be a transformative year for Editas. The recent, highly favorable decision by the U.S. Patent & Trademark Office affirms and upholds the broad and fundamental patents in this field granted to the Broad Institute and exclusively licensed to Editas for human therapeutics. We believe these patents will apply to all CRISPR/Cas9-based medicines.”

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.